NO313080B1 - Farmasöytisk inhaleringspreparat, inhaleringsanordning inneholdende dette, fremgangsmåte for dets fremstilling oganvendelse derav - Google Patents

Farmasöytisk inhaleringspreparat, inhaleringsanordning inneholdende dette, fremgangsmåte for dets fremstilling oganvendelse derav Download PDF

Info

Publication number: NO313080B1
Authority: NO; Norway
Prior art keywords: polypeptide; enhancer; preparation according; hormone; particles
Prior art date: 1993-06-24

Application number

NO19955227A

Other languages

English (en)

Norwegian (no)

Other versions

NO955227L (no

NO955227D0 (no

Inventor

Kjell Goeran Erik Baeckstroem

Carl Magnus Olof Dahlbaeck

Peter Edman

Ann Charlotte Birgit Johansson

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-24

Filing date

1995-12-21

Publication date

2002-08-12

1993-06-24 Priority claimed from SE9302198A external-priority patent/SE9302198D0/xx

1994-02-04 Priority claimed from SE9400371A external-priority patent/SE9400371L/xx

1995-12-21 Application filed by Astra Ab filed Critical Astra Ab

1995-12-21 Publication of NO955227D0 publication Critical patent/NO955227D0/no

1996-02-20 Publication of NO955227L publication Critical patent/NO955227L/no

2002-08-12 Publication of NO313080B1 publication Critical patent/NO313080B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 43
238000002360 preparation method Methods 0.000 title claims description 60
238000000034 method Methods 0.000 title claims description 34
230000008569 process Effects 0.000 title description 6
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 139
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 129
229920001184 polypeptide Polymers 0.000 claims abstract description 126
239000003623 enhancer Substances 0.000 claims abstract description 102
150000001875 compounds Chemical class 0.000 claims abstract description 47
239000000843 powder Substances 0.000 claims abstract description 47
238000010521 absorption reaction Methods 0.000 claims abstract description 43
210000002345 respiratory system Anatomy 0.000 claims abstract description 26
239000011164 primary particle Substances 0.000 claims abstract description 13
230000009885 systemic effect Effects 0.000 claims abstract description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 60
102000004877 Insulin Human genes 0.000 claims description 32
108090001061 Insulin Proteins 0.000 claims description 32
229940125396 insulin Drugs 0.000 claims description 30
239000002245 particle Substances 0.000 claims description 29
239000000825 pharmaceutical preparation Substances 0.000 claims description 15
239000004094 surface-active agent Substances 0.000 claims description 14
210000004072 lung Anatomy 0.000 claims description 13
239000011362 coarse particle Substances 0.000 claims description 11
239000003833 bile salt Substances 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
-1 alkyl glycoside Chemical class 0.000 claims description 9
230000001965 increasing effect Effects 0.000 claims description 9
239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 8
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
229930195725 Mannitol Natural products 0.000 claims description 8
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 8
235000014113 dietary fatty acids Nutrition 0.000 claims description 8
229930195729 fatty acid Natural products 0.000 claims description 8
239000000194 fatty acid Substances 0.000 claims description 8
239000000594 mannitol Substances 0.000 claims description 8
235000010355 mannitol Nutrition 0.000 claims description 8
150000003904 phospholipids Chemical class 0.000 claims description 8
102000002265 Human Growth Hormone Human genes 0.000 claims description 7
108010000521 Human Growth Hormone Proteins 0.000 claims description 7
239000000854 Human Growth Hormone Substances 0.000 claims description 7
150000004665 fatty acids Chemical class 0.000 claims description 7
229930182470 glycoside Natural products 0.000 claims description 7
150000003839 salts Chemical group 0.000 claims description 7
102400000739 Corticotropin Human genes 0.000 claims description 6
101800000414 Corticotropin Proteins 0.000 claims description 6
102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 6
108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 6
102000006771 Gonadotropins Human genes 0.000 claims description 6
108010086677 Gonadotropins Proteins 0.000 claims description 6
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 6
102000003982 Parathyroid hormone Human genes 0.000 claims description 6
108090000445 Parathyroid hormone Proteins 0.000 claims description 6
102100022831 Somatoliberin Human genes 0.000 claims description 6
101710142969 Somatoliberin Proteins 0.000 claims description 6
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 6
229960000258 corticotropin Drugs 0.000 claims description 6
229940028334 follicle stimulating hormone Drugs 0.000 claims description 6
239000002622 gonadotropin Substances 0.000 claims description 6
239000000199 parathyroid hormone Substances 0.000 claims description 6
229960001319 parathyroid hormone Drugs 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 5
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 5
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 5
108010004977 Vasopressins Proteins 0.000 claims description 5
102000002852 Vasopressins Human genes 0.000 claims description 5
229940041967 corticotropin-releasing hormone Drugs 0.000 claims description 5
KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 claims description 5
229960003726 vasopressin Drugs 0.000 claims description 5
229920000858 Cyclodextrin Polymers 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 4
159000000000 sodium salts Chemical class 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
239000008107 starch Substances 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims description 3
101800001288 Atrial natriuretic factor Proteins 0.000 claims description 3
102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 3
101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 3
108010075254 C-Peptide Proteins 0.000 claims description 3
102000055006 Calcitonin Human genes 0.000 claims description 3
108060001064 Calcitonin Proteins 0.000 claims description 3
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 3
108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 3
108060003199 Glucagon Proteins 0.000 claims description 3
102000018997 Growth Hormone Human genes 0.000 claims description 3
108010051696 Growth Hormone Proteins 0.000 claims description 3
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 3
102000009151 Luteinizing Hormone Human genes 0.000 claims description 3
108010073521 Luteinizing Hormone Proteins 0.000 claims description 3
102400000050 Oxytocin Human genes 0.000 claims description 3
101800000989 Oxytocin Proteins 0.000 claims description 3
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 3
102100024028 Progonadoliberin-1 Human genes 0.000 claims description 3
102000003946 Prolactin Human genes 0.000 claims description 3
108010057464 Prolactin Proteins 0.000 claims description 3
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 3
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
239000000556 agonist Substances 0.000 claims description 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
229960004015 calcitonin Drugs 0.000 claims description 3
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 3
229960004281 desmopressin Drugs 0.000 claims description 3
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims description 3
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 3
229960004666 glucagon Drugs 0.000 claims description 3
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 3
239000000122 growth hormone Substances 0.000 claims description 3
239000000832 lactitol Substances 0.000 claims description 3
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
235000010448 lactitol Nutrition 0.000 claims description 3
229960003451 lactitol Drugs 0.000 claims description 3
229940040129 luteinizing hormone Drugs 0.000 claims description 3
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
239000000845 maltitol Substances 0.000 claims description 3
229940035436 maltitol Drugs 0.000 claims description 3
235000010449 maltitol Nutrition 0.000 claims description 3
QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 3
229960001723 oxytocin Drugs 0.000 claims description 3
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 3
239000000813 peptide hormone Substances 0.000 claims description 3
229940097325 prolactin Drugs 0.000 claims description 3
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
239000003488 releasing hormone Substances 0.000 claims description 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
229940075620 somatostatin analogue Drugs 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
235000000346 sugar Nutrition 0.000 claims description 3
229940034208 thyroxine Drugs 0.000 claims description 3
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 3
QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 2
102000009025 Endorphins Human genes 0.000 claims description 2
108010049140 Endorphins Proteins 0.000 claims description 2
108010007979 Glycocholic Acid Proteins 0.000 claims description 2
102000003886 Glycoproteins Human genes 0.000 claims description 2
108090000288 Glycoproteins Proteins 0.000 claims description 2
102000015696 Interleukins Human genes 0.000 claims description 2
108010063738 Interleukins Proteins 0.000 claims description 2
102000004895 Lipoproteins Human genes 0.000 claims description 2
108090001030 Lipoproteins Proteins 0.000 claims description 2
230000023555 blood coagulation Effects 0.000 claims description 2
238000007580 dry-mixing Methods 0.000 claims description 2
230000002708 enhancing effect Effects 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 2
239000003102 growth factor Substances 0.000 claims description 2
230000000144 pharmacologic effect Effects 0.000 claims description 2
229920005862 polyol Polymers 0.000 claims description 2
150000003077 polyols Chemical class 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
238000010298 pulverizing process Methods 0.000 claims description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
150000005846 sugar alcohols Chemical class 0.000 claims description 2
229940014499 ursodeoxycholate Drugs 0.000 claims description 2
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 2
229960005486 vaccine Drugs 0.000 claims description 2
MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 3
102000051325 Glucagon Human genes 0.000 claims 2
102000015731 Peptide Hormones Human genes 0.000 claims 2
108010038988 Peptide Hormones Proteins 0.000 claims 2
229940088597 hormone Drugs 0.000 claims 2
239000005556 hormone Substances 0.000 claims 2
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical group [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims 2
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical group [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 25
239000000126 substance Substances 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
230000000694 effects Effects 0.000 description 10
238000009472 formulation Methods 0.000 description 10
210000002919 epithelial cell Anatomy 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000002156 mixing Methods 0.000 description 8
229960001855 mannitol Drugs 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
239000000654 additive Substances 0.000 description 6
239000003550 marker Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
101000976075 Homo sapiens Insulin Proteins 0.000 description 5
241000700159 Rattus Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 5
230000035699 permeability Effects 0.000 description 5
238000012384 transportation and delivery Methods 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
229940112141 dry powder inhaler Drugs 0.000 description 4
238000001035 drying Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
238000000099 in vitro assay Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000002685 pulmonary effect Effects 0.000 description 4
239000002356 single layer Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
230000002411 adverse Effects 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000001851 biosynthetic effect Effects 0.000 description 3
229910001424 calcium ion Inorganic materials 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000013553 cell monolayer Substances 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
230000008021 deposition Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000005462 in vivo assay Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
150000004671 saturated fatty acids Chemical class 0.000 description 3
229940032147 starch Drugs 0.000 description 3
230000001839 systemic circulation Effects 0.000 description 3
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000007794 irritation Effects 0.000 description 2
239000010410 layer Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000011552 rat model Methods 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229940074410 trehalose Drugs 0.000 description 2
MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 description 1
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
239000001685 glycyrrhizic acid Substances 0.000 description 1
229960004949 glycyrrhizic acid Drugs 0.000 description 1
UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
235000019410 glycyrrhizin Nutrition 0.000 description 1
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940065770 humatrope Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000004682 mucosal barrier function Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229960005141 piperazine Drugs 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
230000004537 potential cytotoxicity Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
210000003456 pulmonary alveoli Anatomy 0.000 description 1
230000004088 pulmonary circulation Effects 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229910052701 rubidium Inorganic materials 0.000 description 1
IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
238000012216 screening Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
229940082004 sodium laurate Drugs 0.000 description 1
229940045845 sodium myristate Drugs 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
XBYKLNAHPCSCOD-UHFFFAOYSA-M sodium;2-hydroxy-5-methoxybenzoate Chemical compound [Na+].COC1=CC=C(O)C(C([O-])=O)=C1 XBYKLNAHPCSCOD-UHFFFAOYSA-M 0.000 description 1
JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001578 tight junction Anatomy 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
239000013638 trimer Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Biological Depolymerization Polymers (AREA)

NO19955227A 1993-06-24 1995-12-21 Farmasöytisk inhaleringspreparat, inhaleringsanordning inneholdende dette, fremgangsmåte for dets fremstilling oganvendelse derav NO313080B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE9302198A SE9302198D0 (sv)	1993-06-24	1993-06-24	Powder preparation for inhalation
SE9400371A SE9400371L (sv)	1994-02-04	1994-02-04	Kompositioner för inhalation
PCT/SE1994/000634 WO1995000128A1 (en)	1993-06-24	1994-06-23	Compositions for inhalation

Publications (3)

Publication Number	Publication Date
NO955227D0 NO955227D0 (no)	1995-12-21
NO955227L NO955227L (no)	1996-02-20
NO313080B1 true NO313080B1 (no)	2002-08-12

Family

ID=26661779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19955227A NO313080B1 (no)	1993-06-24	1995-12-21	Farmasöytisk inhaleringspreparat, inhaleringsanordning inneholdende dette, fremgangsmåte for dets fremstilling oganvendelse derav

Country Status (30)

Country	Link
US (1)	US5952008A (zh)
EP (1)	EP0706383B1 (zh)
JP (2)	JPH09500621A (zh)
KR (1)	KR100372674B1 (zh)
CN (1)	CN1116030C (zh)
AT (1)	ATE206046T1 (zh)
AU (1)	AU692781B2 (zh)
BR (1)	BR9406908A (zh)
CA (1)	CA2166109C (zh)
CZ (1)	CZ287656B6 (zh)
DE (1)	DE69428442T2 (zh)
DK (1)	DK0706383T3 (zh)
EE (1)	EE03222B1 (zh)
EG (1)	EG21484A (zh)
ES (1)	ES2162865T3 (zh)
FI (1)	FI111909B (zh)
HK (1)	HK1009587A1 (zh)
HU (1)	HU226474B1 (zh)
IL (1)	IL110085A (zh)
IS (1)	IS1796B (zh)
MX (1)	MX9404762A (zh)
MY (1)	MY114125A (zh)
NO (1)	NO313080B1 (zh)
NZ (1)	NZ268138A (zh)
PL (1)	PL178261B1 (zh)
PT (1)	PT706383E (zh)
SA (1)	SA94150060B1 (zh)
SK (1)	SK283253B6 (zh)
UA (1)	UA48111C2 (zh)
WO (1)	WO1995000128A1 (zh)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6743777B1 (en) *	1992-03-19	2004-06-01	Eli Lilly And Company	Cyclic peptide antifungal agents and process for preparation thereof
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US6632456B1 (en) *	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US5830853A (en)	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
TW402506B (en) *	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
GB9322014D0 (en)	1993-10-26	1993-12-15	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
CZ295827B6 (cs)	1994-03-07	2005-11-16	Nektar Therapeutics	Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US6051256A (en)	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US6524557B1 (en) *	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
CA2206657C (en) *	1994-12-22	2009-05-19	Astra Aktiebolag	Therapeutic preparation for inhalation containing parathyroid hormone, pth
EE9700138A (et)	1994-12-22	1997-12-15	Astra Aktiebolag	Aerosoolravimvormid
SE9404468D0 (sv) *	1994-12-22	1994-12-22	Astra Ab	Powder formulations
GB9501841D0 (en)	1995-01-31	1995-03-22	Co Ordinated Drug Dev	Improvements in and relating to carrier particles for use in dry powder inhalers
KR19980703876A (ko) *	1995-04-14	1998-12-05	스티븐 엘. 허스트	분산성이 개선된 분말화된 약학적 조성물
US6428771B1 (en) *	1995-05-15	2002-08-06	Pharmaceutical Discovery Corporation	Method for drug delivery to the pulmonary system
US5654007A (en) *	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
GB9515182D0 (en)	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
US6022737A (en) *	1995-11-02	2000-02-08	Amgen Inc.	Formulations for non-viral in vivo transfection in the lungs
US20020052310A1 (en)	1997-09-15	2002-05-02	Massachusetts Institute Of Technology The Penn State Research Foundation	Particles for inhalation having sustained release properties
US20030203036A1 (en)	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) *	1997-02-21	1997-04-09	Bradford Particle Design Ltd	Method and apparatus for the formation of particles
JP2001518916A (ja) *	1997-03-20	2001-10-16	ノボノルディスクアクティーゼルスカブ	結晶インスリンを含有する肺投与のための治療用粉末調合物
US6310038B1 (en)	1997-03-20	2001-10-30	Novo Nordisk A/S	Pulmonary insulin crystals
US5898028A (en) *	1997-03-20	1999-04-27	Novo Nordisk A/S	Method for producing powder formulation comprising an insulin
US6433040B1 (en)	1997-09-29	2002-08-13	Inhale Therapeutic Systems, Inc.	Stabilized bioactive preparations and methods of use
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6946117B1 (en)	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6221378B1 (en)	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US7070799B1 (en) *	1998-02-10	2006-07-04	Generex Pharmaceuticals, Inc.	Method for administering insulin to the buccal region
JPH11246439A (ja) *	1998-03-02	1999-09-14	Hisamitsu Pharmaceut Co Inc	経粘膜用吸収促進剤
US6284282B1 (en) *	1998-04-29	2001-09-04	Genentech, Inc.	Method of spray freeze drying proteins for pharmaceutical administration
TW570805B (en) *	1998-09-01	2004-01-11	Hoffmann La Roche	Water-soluble pharmaceutical composition in an ionic complex
GB9820746D0 (en) *	1998-09-23	1998-11-18	Pharmax Limited	Micronised pharmaceutical compositions
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
AU2879100A (en) *	1999-02-12	2000-08-29	Miles A. Libbey Iii	Formulation and system for intra-oral delivery of pharmaceutical agents
CA2362481C (en) *	1999-03-03	2008-11-04	Eli Lilly And Company	Echinocandin pharmaceutical formulations containing micelle-forming surfactants
ES2204548T3 (es) *	1999-03-03	2004-05-01	Eli Lilly And Company	Complejos de equinocandina/carbohidrato.
US6350432B1 (en)	1999-03-19	2002-02-26	Generex Pharmaceuticals Incorporated	Pressurized container having an aerosolized pharmaceutical composition
WO2000061178A1 (en) *	1999-04-13	2000-10-19	Inhale Therapeutics Systems, Inc.	Pulmonary administration of dry powder formulations for treating infertility
AU779869B2 (en) *	1999-04-13	2005-02-17	Nektar Therapeutics	Pulmonary administration of dry powder formulations for treating infertility
US6485706B1 (en)	1999-06-04	2002-11-26	Delrx Pharmaceutical Corp.	Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
WO2000074754A2 (en)	1999-06-05	2000-12-14	Innovata Biomed Limited	Delivery system
US7169889B1 (en) *	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
DK1808438T3 (da) *	1999-06-29	2014-10-27	Mannkind Corp	Rensning og stabilisering af peptid og proteiner i lægemidler
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP1064934A1 (en)	1999-06-30	2001-01-03	Applied Research Systems ARS Holding N.V.	GRF-containing lyophilized pharmaceutical composition
GB9916316D0 (en) *	1999-07-12	1999-09-15	Quadrant Holdings Cambridge	Dry powder compositions
GB9920839D0 (en)	1999-09-04	1999-11-10	Innovata Biomed Ltd	Inhaler
JP4691298B2 (ja) *	1999-10-12	2011-06-01	科研製薬株式会社	粉末吸入用製剤及びその製造方法
US6156294A (en)	1999-11-28	2000-12-05	Scientific Development And Research, Inc.	Composition and method for treatment of otitis media
US6676930B2 (en)	1999-11-28	2004-01-13	Scientific Development And Research, Inc.	Composition and method for treatment of otitis media
US7029700B2 (en) *	2000-01-14	2006-04-18	Brown University Research Foundation	Micronized freeze-dried particles
US6651655B1 (en)	2000-01-18	2003-11-25	Quadrant Technologies Limited	Inhaled vaccines
US7833549B2 (en) *	2000-01-19	2010-11-16	Mannkind Corporation	Dry powder formulations of antihistamine for nasal administration
US20100303769A1 (en) *	2000-04-06	2010-12-02	Franco Wayne P	Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US7166280B2 (en)	2000-04-06	2007-01-23	Franco Wayne P	Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
TWI290473B (en)	2000-05-10	2007-12-01	Alliance Pharma	Phospholipid-based powders for drug delivery
GB0011807D0 (en) *	2000-05-16	2000-07-05	Quadrant Holdings Cambridge	Formulation for inhalation
IL153705A0 (en)	2000-06-27	2003-07-06	Vectura Ltd	Method of making particles for use in a pharmaceutical composition
WO2002009669A2 (en) *	2000-08-01	2002-02-07	Inhale Therapeutic Systems, Inc.	Apparatus and process to produce particles having a narrow size distribution and particles made thereby
SE516555C2 (sv) *	2000-08-04	2002-01-29	Microdrug Ag	Elektropulver
AU2001281113B2 (en) *	2000-08-07	2006-07-20	Nektar Therapeutics	Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
UA75375C2 (en) *	2000-10-12	2006-04-17	Boehringer Ingelheim Pharma	Method for producing powdery preparations for inhaling
GB0027357D0 (en) *	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
CN1406131A (zh) *	2000-12-25	2003-03-26	株式会社资生堂	活化交感神经的香料组合物
ES2291452T3 (es) *	2001-02-06	2008-03-01	Innovata Biomed Limited	Formulacion bimodal de polvo seco para inhalacion.
US6867183B2 (en)	2001-02-15	2005-03-15	Nobex Corporation	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en)	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
US20030072717A1 (en)	2001-02-23	2003-04-17	Vapotronics, Inc.	Inhalation device having an optimized air flow path
US6858580B2 (en)	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en)	2001-06-04	2010-05-11	Biocon Limited	Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en)	2001-06-04	2004-03-30	Nobex Corporation	Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6913903B2 (en)	2001-09-07	2005-07-05	Nobex Corporation	Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en)	2001-09-07	2004-08-03	Nobex Corporation	Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) *	2001-09-07	2007-01-23	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) *	2001-09-07	2007-12-25	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) *	2001-09-07	2006-04-18	Nobex Corporation	Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en)	2001-09-07	2007-03-27	Biocon Limited	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20050123509A1 (en) *	2001-10-19	2005-06-09	Lehrman S. R.	Modulating charge density to produce improvements in the characteristics of spray-dried proteins
KR20050044523A (ko) *	2001-11-19	2005-05-12	벡톤 디킨슨 앤드 컴퍼니	입자 형태의 약제학적 조성물
GB0128148D0 (en)	2001-11-23	2002-01-16	Innovata Biomed Ltd	Assembly
ES2364636T3 (es)	2001-12-19	2011-09-08	Novartis Ag	Administración pulmonar de aminoglucósidos.
AU2003220125B2 (en)	2002-03-20	2006-06-15	Mannkind Corporation	Inhalation apparatus
SE525027C2 (sv) *	2002-04-12	2004-11-16	Microdrug Ag	Anordning utgörande en pulverlufthyvel
GB0216562D0 (en)	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US20040087543A1 (en) *	2002-04-25	2004-05-06	Zachary Shriver	Methods and products for mucosal delivery
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
US6991800B2 (en) *	2002-06-13	2006-01-31	Vicuron Pharmaceuticals Inc.	Antifungal parenteral products
US7601688B2 (en)	2002-06-13	2009-10-13	Biocon Limited	Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE10234165B4 (de) *	2002-07-26	2008-01-03	Advanced Micro Devices, Inc., Sunnyvale	Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
CN1694689A (zh) *	2002-09-30	2005-11-09	阿库斯菲尔公司	供吸入的缓释多孔微粒
US6962006B2 (en) *	2002-12-19	2005-11-08	Acusphere, Inc.	Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) *	2002-12-19	2004-06-24	Acusphere, Inc.	Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1651248B1 (en) *	2003-07-11	2009-09-09	Novartis AG	Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
KR101137785B1 (ko)	2003-07-18	2012-04-25	백스터 인터내셔널 인코포레이티드	제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물
ES2362038T3 (es)	2003-09-02	2011-06-27	Norton Healthcare Limited	Procedimiento para preparar un medicamento.
JP2007507527A (ja) *	2003-09-30	2007-03-29	スフェリックス，インコーポレイテッド	生物学的に活性なナノ粒子治療用因子
AU2004278013B2 (en) *	2003-10-01	2009-01-15	Momenta Pharmaceuticals, Inc.	Polysaccharides for pulmonary delivery of active agents
US7338171B2 (en) *	2003-10-27	2008-03-04	Jen-Chuen Hsieh	Method and apparatus for visual drive control
CA2552707C (en) *	2004-01-12	2018-03-27	Mannkind Corporation	A method of reducing serum proinsulin levels in type 2 diabetics
US20080248999A1 (en) *	2007-04-04	2008-10-09	Biodel Inc.	Amylin formulations
US20080090753A1 (en) *	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
JO3102B1 (ar)	2004-03-17	2017-09-20	Chiesi Framaceutici S P A	صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
EP1744800B1 (en)	2004-04-21	2016-06-22	Innovata Biomed Limited	Inhaler
DK3520779T3 (da)	2004-04-23	2022-03-21	Cydex Pharmaceuticals Inc	DPI formulering indeholdende sulfoalkylethercyclodextrin
US7244709B2 (en) *	2004-05-10	2007-07-17	Nastech Pharamecutical Company Inc.	Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060052305A1 (en) *	2004-05-10	2006-03-09	Nastech Pharmaceutical Company Inc.	Method of treating osteoporosis using intranasal parathyroid hormone
US20060127320A1 (en) *	2004-05-10	2006-06-15	Nastech Pharmaceutical Company Inc.	Method of delivering parathyroid hormone to a human
KR101309770B1 (ko)	2004-07-19	2013-09-30	바이오콘 리미티드	인슐린―올리고머 접합체，제형 및 이들의 용도
DE602005024413D1 (de)	2004-08-20	2010-12-09	Mannkind Corp	Katalyse der diketopiperazinsynthese
EP2322180B1 (en)	2004-08-23	2015-05-27	MannKind Corporation	Diketopiperazine salts for drug delivery
CA2585859C (en)	2004-10-29	2012-03-06	President And Fellows Of Harvard College	Particles for treatment of pulmonary infection
WO2006091722A2 (en) *	2005-02-23	2006-08-31	Uab Research Foundation	Alkyl-glycoside enhanced vaccination
WO2007019554A2 (en) *	2005-08-08	2007-02-15	Momenta Pharmaceuticals, Inc.	Polysaccharides for delivery of active agents
CN102614131A (zh)	2005-09-14	2012-08-01	曼金德公司	以提高结晶微粒表面对活性试剂的亲和力为基础的药物配制方法
US7713929B2 (en)	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) *	2005-09-29	2007-04-19	Biodel, Inc.	Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) *	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US20070173447A1 (en) *	2005-10-25	2007-07-26	Nastech Pharmaceutical Company Inc.	Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080051332A1 (en) *	2005-11-18	2008-02-28	Nastech Pharmaceutical Company Inc.	Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20070178166A1 (en) *	2005-12-15	2007-08-02	Acusphere, Inc.	Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20070148211A1 (en) *	2005-12-15	2007-06-28	Acusphere, Inc.	Processes for making particle-based pharmaceutical formulations for oral administration
BRPI0707991B8 (pt)	2006-02-22	2021-05-25	Mannkind Corp	métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
AU2007238114B2 (en) *	2006-04-12	2010-10-14	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
US20090054333A1 (en) *	2006-10-17	2009-02-26	Antonio Giordano	Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
JP4830951B2 (ja) *	2007-04-05	2011-12-07	株式会社日立製作所	Ｉｃチップ搬送装置、及び、ｉｃチップ製造方法
KR101234540B1 (ko)	2007-10-16	2013-02-19	바이오콘 리미티드	경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
CA3123813A1 (en)	2007-12-04	2009-06-11	Biogen Chesapeake Llc	Improved glibenclamide formulations and methods for lyophilization thereof and lyophilates provided thereby
CN101951957A (zh) *	2008-01-04	2011-01-19	百达尔公司	胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
IL313823A (en)	2008-06-13	2024-08-01	Mannkind Corp	A dry powder inhaler and system for drug delivery
AU2009259883B2 (en)	2008-06-20	2015-02-05	Mannkind Corporation	An interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (zh)	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
EP2168573A1 (en) *	2008-09-30	2010-03-31	LEK Pharmaceuticals D.D.	Formulations comprising ezetimibe
CN102202682B (zh) *	2008-11-04	2015-08-19	Aska制药株式会社	含促卵泡激素的水性组合物
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
ES2994042T3 (en)	2009-02-26	2025-01-16	Glaxo Group Ltd	Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
CA2754595C (en)	2009-03-11	2017-06-27	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
KR20190090092A (ko)	2009-06-12	2019-07-31	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2496295A1 (en)	2009-11-03	2012-09-12	MannKind Corporation	An apparatus and method for simulating inhalation efforts
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
KR20130117755A (ko)	2010-06-21	2013-10-28	맨카인드 코포레이션	건조 분말 약물 운반 시스템 및 방법
MX350838B (es)	2011-02-11	2017-09-18	Grain Proc Corporation *	Composicion de sal.
MX353285B (es)	2011-04-01	2018-01-05	Mannkind Corp	Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
EP4088736A1 (en)	2011-10-25	2022-11-16	Prothena Biosciences Limited	Humanized anti-amyloid antibody formulations and methods
BR112015000529B1 (pt)	2012-07-12	2022-01-11	Mannkind Corporation	Inalador de pó seco
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
KR102391750B1 (ko)	2013-03-15	2022-04-28	맨카인드 코포레이션	미세결정성 디케토피페라진 조성물 및 방법
BR112016000937A8 (pt)	2013-07-18	2021-06-22	Mannkind Corp	formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CA2920488C (en)	2013-08-05	2022-04-26	Mannkind Corporation	Insufflation apparatus and methods
WO2015148905A1 (en)	2014-03-28	2015-10-01	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US10806770B2 (en)	2014-10-31	2020-10-20	Monash University	Powder formulation

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE556587A (zh) *	1957-01-31	1957-04-11
GB1527605A (en) *	1975-08-20	1978-10-04	Takeda Chemical Industries Ltd	Insulin preparation for intranasal administration
JPS6034925B2 (ja) *	1979-07-31	1985-08-12	帝人株式会社	持続性鼻腔用製剤およびその製造法
JPS5795920A (en) *	1980-12-04	1982-06-15	Teijin Ltd	Remedy for respiratory disease
US4900730A (en) *	1981-01-14	1990-02-13	Toyo Jozo Co., Ltd.	Preparation which promotes the absorption of peptides
SE438261B (sv) *	1981-07-08	1985-04-15	Draco Ab	Anvendning i dosinhalator av ett perforerat membran
ATE23272T1 (de) *	1981-07-08	1986-11-15	Draco Ab	Pulverinhalator.
US5260306A (en) *	1981-07-24	1993-11-09	Fisons Plc	Inhalation pharmaceuticals
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4959358A (en) *	1983-06-06	1990-09-25	Beth Israel Hospital Assn.	Drug administration
US4746508A (en) *	1983-06-06	1988-05-24	Beth Israel Hospital Assn.	Drug administration
US4548922A (en) *	1983-06-06	1985-10-22	Beth Israel Hospital	Drug administration
US4963367A (en) *	1984-04-27	1990-10-16	Medaphore, Inc.	Drug delivery compositions and methods
US5288498A (en) *	1985-05-01	1994-02-22	University Of Utah Research Foundation	Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
JPS61267528A (ja) *	1984-11-26	1986-11-27	Yamanouchi Pharmaceut Co Ltd	吸収促進剤を含有するカルシトニン経鼻剤
SE448277B (sv) *	1985-04-12	1987-02-09	Draco Ab	Indikeringsanordning vid en doseringsanordning for lekemedel
IL78425A (en) *	1985-04-15	1991-05-12	Lilly Co Eli	Intranasal formulation containing insulin
US5122127A (en) *	1985-05-01	1992-06-16	University Of Utah	Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
WO1986006959A1 (en) *	1985-05-22	1986-12-04	Liposome Technology, Inc.	Liposome inhalation method and system
US4847298A (en) *	1985-08-16	1989-07-11	Merck & Co., Inc.	Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
IL77186A0 (en) *	1985-11-29	1986-04-29	Touitou Elka	Pharmaceutical insulin composition
SE453566B (sv) *	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
EP0257915B1 (en) *	1986-08-11	1993-03-10	Innovata Biomed Limited	Pharmaceutical formulations comprising microcapsules
US5179079A (en) *	1986-12-16	1993-01-12	Novo Nordisk A/S	Nasal formulation and intranasal administration therewith
NZ222907A (en) *	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
GB8712176D0 (en) *	1987-05-22	1987-06-24	Cosmas Damian Ltd	Drug delivery system
EP0360340A1 (en) *	1988-09-19	1990-03-28	Akzo N.V.	Composition for nasal administration containing a peptide
SE8803935L (sv) *	1988-10-31	1990-05-01	Kabivitrum Ab	Laekemedelskomposition
US5006343A (en) *	1988-12-29	1991-04-09	Benson Bradley J	Pulmonary administration of pharmaceutically active substances
GB8900267D0 (en) *	1989-01-06	1989-03-08	Riker Laboratories Inc	Narcotic analgesic formulations and apparatus containing same
US4994439A (en) *	1989-01-19	1991-02-19	California Biotechnology Inc.	Transmembrane formulations for drug administration
US5011678A (en) *	1989-02-01	1991-04-30	California Biotechnology Inc.	Composition and method for administration of pharmaceutically active substances
AU639228B2 (en) *	1989-02-17	1993-07-22	Transave, Inc.	Lipid excipient for nasal delivery and topical application
IT8920486A0 (it) *	1989-05-12	1989-05-12	Isf Spa	Composizioni farmaceutiche.
US5176132A (en) *	1989-05-31	1993-01-05	Fisons Plc	Medicament inhalation device and formulation
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
GB8921222D0 (en) *	1989-09-20	1989-11-08	Riker Laboratories Inc	Medicinal aerosol formulations
US5707644A (en) *	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
GB9001635D0 (en) *	1990-01-24	1990-03-21	Ganderton David	Aerosol carriers
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
US5118494A (en) *	1990-03-23	1992-06-02	Minnesota Mining And Manufacturing Company	Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JPH05963A (ja) *	1990-04-13	1993-01-08	Toray Ind Inc	ポリペプチド類組成物
US5192548A (en) *	1990-04-30	1993-03-09	Riker Laboratoires, Inc.	Device
AU7908791A (en) *	1990-05-08	1991-11-27	Liposome Technology, Inc.	Direct spray-dried drug/lipid powder composition
ES2117642T3 (es) *	1990-05-10	1998-08-16	Bechgaard Int Res	Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
IL99699A (en) *	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5086775A (en) *	1990-11-02	1992-02-11	University Of Rochester	Method and apparatus for using Doppler modulation parameters for estimation of vibration amplitude
GB9024365D0 (en) *	1990-11-09	1991-01-02	Glaxo Group Ltd	Medicaments
JP3507486B2 (ja) *	1991-03-15	2004-03-15	アムジエン・インコーポレーテツド	顆粒球コロニー刺激因子の肺内投与
CA2127877A1 (en) *	1992-01-21	1993-07-22	Robert M. Platz	Improved process for preparing micronized polypeptide drugs
EP0566135A1 (en) *	1992-04-17	1993-10-20	Takeda Chemical Industries, Ltd.	Transmucosal composition comprising a peptide and a cytidine derivative
DE69332240T2 (de) *	1992-06-12	2003-04-10	Teijin Ltd., Osaka	Ultrafeines pulver zur inhalation und dessen herstellung
WO1994007514A1 (en) *	1992-09-29	1994-04-14	Inhale Therapeutic Systems	Pulmonary delivery of active fragments of parathyroid hormone
ES2154673T3 (es) *	1993-01-29	2001-04-16	Aradigm Corp	Suministro intrapulmonar de hormonas.
US5364838A (en) *	1993-01-29	1994-11-15	Miris Medical Corporation	Method of administration of insulin
BE1006873A6 (nl) *	1993-03-26	1995-01-10	Merkus Franciscus W H M	Toedieningsformulering voor nasale insuline toediening.
DE69413528T2 (de) *	1993-04-06	1999-05-06	Minnesota Mining And Mfg. Co., Saint Paul, Minn.	Vorrichtung zum deagglomerieren für trockenpulverinhalatoren
US5661130A (en) *	1993-06-24	1997-08-26	The Uab Research Foundation	Absorption enhancers for drug administration
US5830853A (en) *	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
US5506203C1 (en) *	1993-06-24	2001-02-06	Astra Ab	Systemic administration of a therapeutic preparation
US5747445A (en) *	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
TW402506B (en) *	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
GB9314614D0 (en) *	1993-07-14	1993-08-25	Minnesota Mining & Mfg	Dry powder inhalers
US5514670A (en) *	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides

1994
- 1994-06-21 IS IS4179A patent/IS1796B/is unknown
- 1994-06-22 EG EG36794A patent/EG21484A/xx active
- 1994-06-22 MY MYPI94001613A patent/MY114125A/en unknown
- 1994-06-22 IL IL11008594A patent/IL110085A/en not_active IP Right Cessation
- 1994-06-23 PL PL94312210A patent/PL178261B1/pl not_active IP Right Cessation
- 1994-06-23 ES ES94919961T patent/ES2162865T3/es not_active Expired - Lifetime
- 1994-06-23 NZ NZ268138A patent/NZ268138A/en not_active IP Right Cessation
- 1994-06-23 CZ CZ19953393A patent/CZ287656B6/cs not_active IP Right Cessation
- 1994-06-23 AU AU70902/94A patent/AU692781B2/en not_active Ceased
- 1994-06-23 UA UA95125418A patent/UA48111C2/uk unknown
- 1994-06-23 MX MX9404762A patent/MX9404762A/es not_active IP Right Cessation
- 1994-06-23 JP JP7502737A patent/JPH09500621A/ja not_active Withdrawn
- 1994-06-23 SK SK1602-95A patent/SK283253B6/sk not_active IP Right Cessation
- 1994-06-23 EP EP94919961A patent/EP0706383B1/en not_active Expired - Lifetime
- 1994-06-23 CN CN94192867A patent/CN1116030C/zh not_active Expired - Fee Related
- 1994-06-23 WO PCT/SE1994/000634 patent/WO1995000128A1/en active IP Right Grant
- 1994-06-23 KR KR1019950705905A patent/KR100372674B1/ko not_active Expired - Fee Related
- 1994-06-23 PT PT94919961T patent/PT706383E/pt unknown
- 1994-06-23 CA CA002166109A patent/CA2166109C/en not_active Expired - Fee Related
- 1994-06-23 BR BR9406908A patent/BR9406908A/pt not_active Application Discontinuation
- 1994-06-23 DE DE69428442T patent/DE69428442T2/de not_active Expired - Lifetime
- 1994-06-23 HU HU9503660A patent/HU226474B1/hu not_active IP Right Cessation
- 1994-06-23 AT AT94919961T patent/ATE206046T1/de active
- 1994-06-23 DK DK94919961T patent/DK0706383T3/da active
- 1994-07-05 SA SA94150060A patent/SA94150060B1/ar unknown
- 1994-11-23 EE EE9400457A patent/EE03222B1/xx not_active IP Right Cessation
1995
- 1995-12-21 NO NO19955227A patent/NO313080B1/no not_active IP Right Cessation
- 1995-12-22 FI FI956228A patent/FI111909B/fi not_active IP Right Cessation
1997
- 1997-05-19 US US08/858,122 patent/US5952008A/en not_active Expired - Lifetime
1998
- 1998-09-01 HK HK98110333A patent/HK1009587A1/xx not_active IP Right Cessation
2005
- 2005-11-09 JP JP2005325089A patent/JP2006089497A/ja active Pending

Also Published As

Publication number	Publication date
DE69428442D1 (de)	2001-10-31
JPH09500621A (ja)	1997-01-21
EG21484A (en)	2001-11-28
PT706383E (pt)	2002-03-28
KR100372674B1 (ko)	2003-05-12
AU7090294A (en)	1995-01-17
DK0706383T3 (da)	2001-12-10
CA2166109A1 (en)	1995-01-05
CZ287656B6 (en)	2001-01-17
EP0706383A1 (en)	1996-04-17
CA2166109C (en)	2004-12-14
HK1009587A1 (en)	1999-06-04
NO955227L (no)	1996-02-20
DE69428442T2 (de)	2002-07-11
EP0706383B1 (en)	2001-09-26
MY114125A (en)	2002-08-30
PL178261B1 (pl)	2000-03-31
HU226474B1 (en)	2009-01-28
AU692781B2 (en)	1998-06-18
IS4179A (is)	1994-12-25
PL312210A1 (en)	1996-04-01
JP2006089497A (ja)	2006-04-06
BR9406908A (pt)	1996-04-02
MX9404762A (es)	1995-01-31
HU9503660D0 (en)	1996-02-28
CN1116030C (zh)	2003-07-30
FI111909B (fi)	2003-10-15
IS1796B (is)	2001-12-31
EE03222B1 (et)	1999-10-15
CN1127471A (zh)	1996-07-24
NO955227D0 (no)	1995-12-21
FI956228A0 (fi)	1995-12-22
US5952008A (en)	1999-09-14
SA94150060B1 (ar)	2005-05-31
HUT75066A (en)	1997-03-28
ES2162865T3 (es)	2002-01-16
IL110085A0 (en)	1994-10-07
ATE206046T1 (de)	2001-10-15
IL110085A (en)	2001-06-14
SK283253B6 (sk)	2003-04-01
SK160295A3 (en)	1997-03-05
FI956228L (fi)	1995-12-22
UA48111C2 (uk)	2002-08-15
WO1995000128A1 (en)	1995-01-05
CZ339395A3 (en)	1996-05-15
NZ268138A (en)	1997-10-24

Publication	Publication Date	Title
NO313080B1 (no)	2002-08-12	Farmasöytisk inhaleringspreparat, inhaleringsanordning inneholdende dette, fremgangsmåte for dets fremstilling oganvendelse derav
US6794357B1 (en)	2004-09-21	Compositions for inhalation
US6632456B1 (en)	2003-10-14	Compositions for inhalation
EP0799030B1 (en)	2002-07-24	Powder formulations containing melezitose as a diluent
AU692780B2 (en)	1998-06-18	Therapeutic preparation for inhalation
US5747445A (en)	1998-05-05	Therapeutic preparation for inhalation
US6846801B1 (en)	2005-01-25	Systemic administration of a therapeutic preparation
KR100428281B1 (ko)	2004-06-16	펩티드및단백질의에어로졸제제
US6165976A (en)	2000-12-26	Therapeutic preparation for inhalation
US20010003739A1 (en)	2001-06-14	Systemic administration of a therapeutic preparation
RU2159108C2 (ru)	2000-11-20	Композиции для ингаляции
NZ328475A (en)	2001-04-27	A pharmaceutical composition containing a polypeptide up to 40 kD and an enhancer for systemic delivery by inhalation

Legal Events

Date	Code	Title	Description
2013-02-04	MM1K	Lapsed by not paying the annual fees